Literature DB >> 19111875

Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma.

John M Maris1.   

Abstract

Aurora A is a mitotic kinase that is essential for regulation of the G2/M checkpoint. In this issue of Cancer Cell, Otto et al. report that Aurora A interacts with MYCN, a potent oncogene in human neuroblastoma, and sequesters it from proteolytic degradation. This surprising finding further enhances Aurora A's potential as a therapeutic target.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19111875     DOI： 10.1016/j.ccr.2008.12.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

Authors:  Kristopher R Bosse; Sharon J Diskin; Kristina A Cole; Andrew C Wood; Robert W Schnepp; Geoffrey Norris; Le B Nguyen; Jayanti Jagannathan; Michael Laquaglia; Cynthia Winter; Maura Diamond; Cuiping Hou; Edward F Attiyeh; Yael P Mosse; Vanessa Pineros; Eva Dizin; Yongqiang Zhang; Shahab Asgharzadeh; Robert C Seeger; Mario Capasso; Bruce R Pawel; Marcella Devoto; Hakon Hakonarson; Eric F Rappaport; Irmgard Irminger-Finger; John M Maris
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

Review 2.  Neuroblastoma: biology and staging.

Authors:  Sabine Mueller; Katherine K Matthay
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

3.  AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment.

Authors:  Wei He; Min-Guang Zhang; Xiao-Jing Wang; Shan Zhong; Yuan Shao; Yu Zhu; Zhou-Jun Shen
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

Review 4.  Molecular aspects of prostate cancer with neuroendocrine differentiation.

Authors:  Qi Li; Connie S Zhang; Yifen Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

5.  Myc proteins as therapeutic targets.

Authors:  W C Gustafson; W A Weiss
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

6.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

7.  Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Authors:  Hernan Carol; Ingrid Boehm; C Patrick Reynolds; Min H Kang; John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; Jianrong Wu; Amy E Wozniak; Yu Yang; Mark Manfredi; Jeffrey Ecsedy; Jianmin Wang; Geoffrey Neale; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Cancer Chemother Pharmacol       Date:  2011-03-30       Impact factor: 3.333

8.  Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation.

Authors:  Laurent Sakka; Nathalie Delétage; Maryse Chalus; Youssef Aissouni; Valérie Sylvain-Vidal; Stéphane Gobron; Guillaume Coll
Journal:  Oncotarget       Date:  2017-06-27

9.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

10.  Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF.

Authors:  Alessio Polacchini; Clara Albani; Gabriele Baj; Andrea Colliva; Patrizia Carpinelli; Enrico Tongiorgi
Journal:  Biol Open       Date:  2016-07-15       Impact factor: 2.422
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.